| Name | 2-(2-chlorophenyl)-2,2-diphenylacetonitrile |
|---|---|
| Synonyms |
(2-chlorophenyl)-diphenylacetonitrile
TRAM-39 TRAM 39 |
| Description | TRAM-39 is a selective blocker of intermediate conductance Ca2+-activated K+ (IKCa) channels. TRAM-39 inhibits KCa3.1 channel with an IC50 value of 60 nM. TRAM-39 can be used for the research of ataxia, epilepsy, memory disorders, schizophrenia and Parkinson’s disease[1][2][3][4]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 60 nM (KCa3.1 channel)[4] |
| In Vitro | TRAM-39 (1 μM) reduces the peak amplitude of gKCa2 in sympathetic LAH neurons (mean percentage change 56%) in BAE cells[2]. TRAM-39 (200 nM) diminishes lipopolysaccharide (LPS)-induced cryptdin release from paneth cells[3]. |
| In Vivo | TRAM-39 (1 μM; adds to the perfusate) fully blocks all IKCa channels in multicellular preparations[1]. |
| Molecular Formula | C20H14ClN |
|---|---|
| Molecular Weight | 303.78500 |
| Exact Mass | 303.08100 |
| PSA | 23.79000 |
| LogP | 5.19798 |
| Storage condition | -20°C |